ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
May 06 2019 - 8:00AM
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a
biopharmaceutical company focused on the development of therapeutic
drugs for the treatment of liver disease arising from non-alcoholic
steatohepatitis (NASH) and chronic viral infection, announced today
that the Nasdaq Hearings Panel has granted the Company’s request
for continued listing on The Nasdaq Capital Market, subject to
compliance with certain conditions.
The Company is diligently working to evidence full compliance
with all applicable requirements for continued listing on The
Nasdaq Capital Market, in particular the $1.00 minimum bid price
requirement.
About ContraVir Pharmaceuticals ContraVir is a
clinical stage biopharmaceutical company focused on the development
of targeted therapies for liver disease arising from non-alcoholic
steatohepatitis (NASH) and chronic hepatitis virus infection (HBV,
HCV, HDV). The company’s lead drug candidate, CRV431, reduces liver
fibrosis and hepatocellular carcinoma tumor burden in experimental
models of NASH. Preclinical studies also have demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms. These diverse therapeutic activities result from
CRV431's potent inhibition of cyclophilin enzymes, which are
involved in many disease processes. Currently in clinical phase
development, CRV431 shows potential to play an important role in
the overall treatment of liver disease - from triggering events
through to end-stage disease. For more information, please
visit www.contravir.com.
Forward Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words
such as “anticipate,” “believe,” “forecast,” “estimated,” and
“intend,” among others. These forward-looking statements are based
on ContraVir’s current expectations and actual results could differ
materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in ContraVir’s Form 10-K for the year ended December 30,
2018 and other periodic reports filed with the Securities and
Exchange Commission.
For further information, please contact:
Stephen Kilmer ContraVir Investor Relations(646)
274-3580skilmer@contravir.com
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024